CMS Decision Helps Unlock the Potential of Next-Generation Testing


Precision’s David Parker, PhD covers key takeaways for the oncology community following the Centers for Medicare & Medicaid (CMS) recent announcement on final national coverage determination (NCD)1 expanding coverage for next-generation sequencing (NGS) tests used as companion diagnostics for patients with cancer.

To read the full article, please click here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.